Wildcatisland wrote:Came across this today whilst googling. Anyone know anything about the drug?
http://www.medpagetoday.com/MeetingCoverage/KCA/16207
Emma
foretinib (GSK1363089), XL880 (?) Emma,
My husband talked to clinical trial researchers about getting on this, but the trial was closed. They told him that there was "reasonably effective" in PRCC, but the results were very "uneven" as to who it helped, and who it didn't. They said the side effects were slightly less than Sutent. They put him on a list for "Possible Phase-3 trial, but aren't sure when/if there will be one.
They also told him, that you can't just jump from one drug or trial to the next, because then a "new drug trail", may not want you if you've ever taken more than one drug.
C-Met inhibitor(PF-02341066) , for small cell ca like PRCC, that Pfizer is doing:
He was discouraged from trying the C-Met inhibitor at this time, because "It may or may NOT help...we have no guarantee that it will help you, and it may keep you from going on another drug that looks more promising, whenever that drug may or may not come up.
They've not said "NO", but are "discouraging" changing from Sutent. But everybody says Sutent is better in Clear cell, than Papillary.....So....do they really understand that, while we are on a drug (Sutent) that is considered "Palliative" I HATE THAT WORD, as a patient, we may WANT to gamble on the next new drug....taking our chances whether it will work for US, or not! How LONG can we wait w/PRCC mets before it's too late, and shouldn't it be up to US to decide whether to take the risk or not.
My husband is 78. When do we run out of time, and need to take a risk on a new drug, be it foretinib, or the new C-Met inhibitor(PF-02341066), for small cell ca (like PRCC), that Pfizer is doing?
This drug is being talked about in many, many articles in Uro journals etc., and because it has worked well for PRCC in a Petri dish, and in rats. The C-Met trial director told Tom that they feel good about how it works in lung ca. that have this small cell molecule sensitivity to C-Met inhibitors, and anyone, who has any small cell cancer types, that are tested to have this molecule sensitivity, will be accepted in the Phaze-1 trial. Phaze-1 is only to decide the dosage! It would take Phaze-2/3 to see how well it works in DESTROYING people's ca.
It is SO difficult to deal with as a layperson, and I am plagued with distrust of the motivations of the drug companies and doctors! I assume that they have to harden themselves from the panic, pain, and urgency that patients and caregivers are going through...or it would interfere with their jobs....but Damn!
Sarah
wife of Tom When the world says, "Give up", Hope whispers, "Try it one more time."
